XML 25 R12.htm IDEA: XBRL DOCUMENT
v3.25.2

Real Estate and Other Investments | 6 Months Ended
--- | ---
Jun. 30, 2025
Real Estate [Abstract] |
Real Estate and Other Investments | Real Estate and Other Investments As of June 30, 2025, we owned 341 properties located in 34 states and Washington, D.C., including 21 properties classified as held for sale and one closed senior living community, and we owned an equity interest in each of two unconsolidated joint ventures that own medical office and life science properties located in five states. Dispositions: The table below represents the sale prices, excluding closing costs, of our dispositions for the six months ended June 30, 2025. We do not believe these sales represent a strategic shift in our business. As a result, the results of operations for these properties are included in continuing operations through the date of sale of such properties in our condensed consolidated statements of comprehensive income (loss).
Date of Sale |  | State |  | Type of Property |  | Number of Properties |  |  |  |  | Sales Price |  | Gain (Loss) on Sale |  |
January 2025 |  | Delaware |  | Senior Living (SHOP) |  | 1 |  |  |  |  | $ | 2,900 |  |  | $ | 1,263 |  |  |
January 2025 |  | California |  | Life Science (1) |  | 3 |  |  |  |  | 159,025 |  |  | 9,723 |  |  |
February 2025 |  | Arizona |  | Life Science |  | 1 |  |  |  |  | 16,800 |  |  | 65 |  |  |
February 2025 |  | Various |  | Senior Living (1) |  | 18 |  |  |  |  | 135,000 |  |  | 97,560 |  |  |
March 2025 |  | Connecticut |  | Medical Office (1) |  | 1 |  |  |  |  | 7,100 |  |  | 1,529 |  |  |
May 2025 |  | Tennessee |  | Senior Living (SHOP) |  | 1 |  |  |  |  | 11,150 |  |  | (5,261) |  |  |
May 2025 |  | Missouri |  | Medical Office |  | 1 |  |  |  |  | 5,250 |  |  | (2,168) |  |  |
|  |  |  |  |  | 26 |  |  |  |  | $ | 337,225 |  |  | $ | 102,711 |  |  |
(1)We used aggregate net proceeds of $299,158 from the sales of these properties to partially redeem our outstanding senior secured notes due 2026. As of June 30, 2025, we had 21 properties classified as held for sale in our condensed consolidated balance sheet as follows:
Segment |  | Number of Properties |  | Real Estate Properties, Net |  |
SHOP |  | 15 |  | $ | 69,610 |  |  |
Medical Office and Life Science (1) |  | 5 |  | 18,734 |  |  |
All Other |  | 1 |  | 2,246 |  |  |
|  | 21 |  | $ | 90,590 |  |  |
(1)The net proceeds from the sale of two of these properties are required to be used to partially redeem our outstanding senior secured notes due 2026, if the sales of those properties are completed. We expect to sell these properties during the fourth quarter of 2025 for an aggregate sales price of $13,118, excluding closing costs. Subsequent to June 30, 2025, we sold three properties for an aggregate sales price of $8,800, excluding closing costs. As of August 1, 2025, we had 49 properties under agreements or letters of intent to sell for an aggregate sales price of $279,923, excluding closing costs. The net proceeds from the sales of 11 of these properties, which have an expected aggregate sales price of $90,588, excluding closing costs, are required to be used to partially redeem our outstanding senior secured notes due 2026, if the sales of such properties are completed. We may not complete the sales of any or all of the properties we currently plan to sell. Also, we may sell some or all of these properties at amounts that are less than currently expected and/or less than the carrying values of such properties, and we may incur losses on any such sales as a result. Impairment: We regularly evaluate our assets for indicators of impairment. Impairment indicators may include declining tenant or resident occupancy, weak or declining profitability from the property, decreasing tenant cash flows or liquidity, our decision to dispose of an asset before the end of its estimated useful life and legislative, market or industry changes that could permanently reduce the value of an asset. If indicators of impairment are present, we evaluate the carrying value of the affected assets by comparing it to the expected future undiscounted cash flows to be generated from those assets. The future cash flows are subjective and are based in part on assumptions regarding hold periods, market rents and terminal capitalization rates. If the sum of these expected future cash flows is less than the carrying value, we reduce the net carrying value of the asset to its estimated fair value. During the six months ended June 30, 2025, we recorded impairment charges of $52,266 to adjust the carrying value of 10 medical office properties to their estimated fair values. We sold one of these properties during the six months ended June 30, 2025. Four of these properties were classified as held for sale in our condensed consolidated balance sheet as of June 30, 2025. Subsequent to June 30, 2025, we sold two of these 10 properties, and as of August 1, 2025, seven properties were under agreements or letters of intent to sell. During the six months ended June 30, 2025, we also recorded impairment charges of $17,199 to adjust the carrying value of 10 senior living communities in our senior housing operating portfolio, or SHOP, to their estimated fair values. These communities were classified as held for sale in our condensed consolidated balance sheet as of June 30, 2025. Investments and Capital Expenditures: The following is a summary of capital expenditures, development, redevelopment and other activities for the periods presented:
|  | Three Months Ended June 30, |  | Six Months Ended June 30,
|  | 2025 |  | 2024 |  | 2025 |  | 2024
SHOP fixed assets and capital improvements |  | $ | 24,283 |  |  | $ | 21,623 |  |  | $ | 45,398 |  |  | $ | 31,714 |
Medical Office and Life Science Portfolio capital expenditures: |  |  |  |  |  |  |  |
Lease related costs (1) |  | 3,528 |  |  | 6,409 |  |  | 7,375 |  |  | 12,438 |
Building improvements (2) |  | 1,518 |  |  | 1,852 |  |  | 3,042 |  |  | 2,771 |
Recurring capital expenditures - Medical Office and Life Science Portfolio |  | 5,046 |  |  | 8,261 |  |  | 10,417 |  |  | 15,209 |
Wellness centers lease related costs (1) |  | — |  |  | 4,591 |  |  | — |  |  | 11,514 |
Total recurring capital expenditures |  | $ | 29,329 |  |  | $ | 34,475 |  |  | $ | 55,815 |  |  | $ | 58,437 |
Development, redevelopment and other activities - SHOP (3) |  | $ | 4,660 |  |  | $ | 5,705 |  |  | $ | 10,228 |  |  | $ | 6,894 |
Development, redevelopment and other activities - Medical Office and Life Science Portfolio (3) |  | — |  |  | 1,112 |  |  | — |  |  | 1,825 |
Total development, redevelopment and other activities |  | $ | 4,660 |  |  | $ | 6,817 |  |  | $ | 10,228 |  |  | $ | 8,719 |
Capital expenditures by segment: |  |  |  |  |  |  |  |
SHOP |  | $ | 28,943 |  |  | $ | 27,328 |  |  | $ | 55,626 |  |  | $ | 38,608 |
Medical Office and Life Science Portfolio |  | 5,046 |  |  | 9,373 |  |  | 10,417 |  |  | 17,034 |
All Other - wellness centers |  | — |  |  | 4,591 |  |  | — |  |  | 11,514 |
Total capital expenditures |  | $ | 33,989 |  |  | $ | 41,292 |  |  | $ | 66,043 |  |  | $ | 67,156 |
(1)Includes capital expenditures to improve tenants' space or amounts paid directly to tenants to improve their space and other leasing related costs, such as brokerage commissions and tenant inducements. (2)Includes capital expenditures to replace obsolete building components that extend the useful life of existing assets or other improvements to increase the marketability of the property. (3)Includes capital expenditures that reposition a property or result in change of use or new sources of revenue. Equity Method Investments in Unconsolidated Joint Ventures: As of June 30, 2025, we had equity investments in unconsolidated joint ventures as follows:
Equity Method Investments in Joint Venture |  | DHC Ownership |  | DHC Carrying Value of Investment at June 30, 2025 |  | Number of Properties |  | State |  | Square Feet
Seaport Innovation LLC |  | 10% |  | $ | 94,415 |  |  | 1 |  | MA |  | 1,134,479 |
The LSMD Fund REIT LLC |  | 20% |  | 44,736 |  |  | 10 |  | CA, MA, NY, TX, WA |  | 1,068,763 |
|  |  |  | $ | 139,151 |  |  | 11 |  |  |  | 2,203,242 |
The following table provides a summary of the mortgage debts of these joint ventures as of June 30, 2025:
Joint Venture |  | Coupon Rate |  | Maturity Date |  | Principal Balance (1)
Mortgage Notes Payable (secured by one property in Massachusetts) (2) (3) |  | 3.53% |  | 11/6/2028 |  | $ | 620,000 |
Mortgage Notes Payable (secured by nine properties in five states) (4) |  | 3.46% |  | 2/11/2032 |  | 189,800 |
Mortgage Notes Payable (secured by one property in California) (4) (5) |  | 6.21% |  | 2/9/2026 |  | 266,825 |
|  | 4.18% |  |  |  | $ | 1,076,625 |
(1)Amounts are not adjusted for our minority equity interest. (2)We provide certain guaranties on this debt. (3)This mortgage loan requires interest-only payments until the anticipated repayment date on August 6, 2026, at which time all accrued and unpaid interest along with the principal balance of $620,000 is expected to be repaid. This mortgage loan matures on November 6, 2028 and any unpaid principal from the anticipated repayment date through the maturity date bears interest at a variable rate of the greater of 6.53% or the then effective U.S. swap rate terminating on the maturity date plus 5.00%. (4)The debt securing these properties is non-recourse to us. (5)The joint venture has one remaining one-year extension option for the maturity date of this mortgage loan, subject to satisfaction of certain conditions, and this mortgage loan requires that interest be paid at an annual rate of the one-month term secured overnight financing rate, or SOFR, plus a premium of 1.90%. The joint venture has purchased an interest rate cap through February 2026 with a SOFR strike rate equal to 5.74%. We account for the unconsolidated joint venture for 10 medical office and life science properties in which we own a 20% equity interest, or the LSMD JV, and the unconsolidated joint venture for a life science property located in Boston, Massachusetts in which we own a 10% equity interest, or the Seaport JV, using the equity method of accounting under the fair value option. We recognized changes in the fair value of our investments in our unconsolidated joint ventures of $2,654 and $(21,493) during the three months ended June 30, 2025 and 2024, respectively, and $3,792 and $(19,880) during the six months ended June 30, 2025 and 2024, respectively. These amounts are included in equity in net earnings (losses) of investees in our condensed consolidated statements of comprehensive income (loss). See Note 6 for further information regarding the valuation of our investment in these joint ventures. Equity Method Investment in AlerisLife: As of June 30, 2025, we owned approximately 34.0% of the outstanding common shares of AlerisLife Inc., or AlerisLife. We do not control the activities that are most significant to AlerisLife and, as a result, we account for our non-controlling interest in AlerisLife using the equity method of accounting. As of June 30, 2025, our investment in AlerisLife had a carrying value of $8,418. The cost basis of our investment in AlerisLife exceeded our proportionate share of AlerisLife's total stockholders' equity book value on the date of acquisition of our initial interest in AlerisLife, which was February 16, 2024, by an aggregate of $29,500. As required under GAAP, we are amortizing this difference to equity in earnings of an investee over 21 years, the weighted average remaining useful life of the real estate assets owned by AlerisLife and the intangible contract asset with us as of the date of acquisition. We recorded amortization of the basis difference of $351 and $352 for the three months ended June 30, 2025 and 2024, respectively, and $702 and $526 for the six months ended June 30, 2025 and 2024, respectively. We recognized income of $77 and $8,834 related to our investment in AlerisLife for the three months ended June 30, 2025 and 2024, respectively, and $75 and $8,945 for the six months ended June 30, 2025 and 2024, respectively. These amounts are included in equity in net earnings (losses) of investees in our condensed consolidated statements of comprehensive income (loss). On February 14, 2025, AlerisLife paid an aggregate cash dividend of $50,000 to its stockholders. Our pro rata share of this cash dividend was $17,000 and our basis in the equity method investment in AlerisLife was reduced by such amount. On July 15, 2025, AlerisLife paid an aggregate cash dividend of $10,000 to its stockholders. Our pro rata share of this cash dividend was $3,400 and our basis in the equity method investment in AlerisLife will be reduced by such amount. See Note 11 for further information regarding our investment in AlerisLife. Other: In September 2022, certain of our managed senior living communities located in Florida experienced hurricane related damage. We carry comprehensive property, casualty, flood and business interruption insurances which covered our losses at these senior living communities, subject to a deductible. During the six months ended June 30, 2025, we recognized a gain on insurance recoveries of $7,522 as a result of insurance proceeds received for these damaged senior living communities and the closing of the associated claim.

X
- References No definition available. + Details
Name: | us-gaap_RealEstateAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for certain real estate investment financial statements, real estate investment trust operating support agreements, real estate owned, retail land sales, time share transactions, as well as other real estate related disclosures. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 974 -SubTopic 720 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477728/974-720-50-1 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 976 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/976/tableOfContent Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 978 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/978/tableOfContent Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 970 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/970/tableOfContent Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 972 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/972/tableOfContent Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 974 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/974/tableOfContent + Details
Name: | us-gaap_RealEstateDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration